The work showcases Yale’s commitment to precision medicine by using healthcare data to improve early diagnosis and treatment of cardiovascular diseases.

Researchers tested the AI model across eight distinct cohorts in the United States and Europe, demonstrating its ability to flag at-risk individuals for further evaluation.

An observational TRACE-AI Network Study is underway at 13 health centers to assess multimodal AI tools for detecting transthyretin amyloid cardiomyopathy at scale.

The AI model was trained on thousands of de-identified ECGs and refined with data from hundreds of diagnosed patients to learn disease-associated patterns.

The tool has FDA Breakthrough Devices Program designation and is currently under FDA review, indicating potential expedited clinical availability.

Yale School of Medicine researchers developed an AI platform that detects amyloid cardiomyopathy from ECG images accessible via smartphones.

Early detection can alter disease trajectories and potentially save lives, according to the researchers.

The article highlights the global burden of cardiovascular diseases and the rising importance of AI-enabled screening to improve outcomes.

The model’s ability to predict risk from simple, non-invasive data is likened to scanning an ECG image for easy interpretation.

The platform aims to narrow the diagnostic funnel, enabling earlier intervention and potentially preventing progression to heart failure.

The study focuses on transthyretin amyloid cardiomyopathy, a form caused by misfolded transthyretin proteins accumulating on the heart.

Key Yale researchers include Rohan Khera and Philip Croon, with Khera directing the Cardiovascular Data Science Lab.